Status:
COMPLETED
Role of Turmeric on Oxidative Modulation in ESRD Patients
Lead Sponsor:
Shiraz University of Medical Sciences
Conditions:
End Stage Renal Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Despite advances in prevention of cardiovascular diseases, the incidence of accelerated atherosclerosis in hemodialysis (HD) patients has still remained high. Oxidative stress is considered as a major...
Detailed Description
End-stage renal disease (ESRD) is a state of oxidative stress, due to uremic oxidant mediator's accumulation, the activation of phagocytic oxidative metabolism by the dialysis membrane, intravenous ir...
Eligibility Criteria
Inclusion
- having the age of 18 years and more,
- receiving 4-hour HD treatments 3 times per week at least for three months,
- administering no other antioxidant medications
Exclusion
Key Trial Info
Start Date :
April 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT01906840
Start Date
April 1 2011
End Date
August 1 2012
Last Update
July 24 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.